Bibliography
- STEWART S, MACINTYRE K,HOLE DJ, CAPEWELL S,MCMURRAY JJV: More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Ear: J. Heart Fail. (2001) 3:315–322.
- KELLY D: Our future society: a global challenge. Circulation (1997) 95:2459–2464.
- THE DIGITALIS INVESTIGATION GROUP: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl. J. Med. (1997) 336:525–533.
- PACKER M, CARVER JR,RODEHEFFER RJ et al.: Effect of oral milrinone on mortality in severe heart failure. N Engl. I Med. (1991) 325:1468–1475.
- THACKRAY S, COLETTA A, JONES Pet al.: Clinical trials update: Highlights of the scientific sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society ofCardiology, CONTAK-D, CHRISTMAS, OPTIME-CHE Eur. I Heart Fail. (2001) 3:491–194.
- MOE GW, ROULEAU JL, CHARBONNEAU L et al.: Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. Am. Heart J. (2000) 139:587–595.
- O'CONNOR CM, GATTIS WA, URETSKY B et al.: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am. Heart" (1999) 138:78–86.
- WANG X, LI MX, SPYRACOPOULOS L et al.: Structure of the C-domain of human cardiac troponin C in complex with the Ca2+ sensitizing drug EMD 57033." Biol. Chem. (2001) 276:25456–25466.
- DOGGRELL SA, BROWN L: EMD 57033. Drugs Future (2002) 27:14–20.
- FIGGITT DP, GILLIES PS, GOA KL: Levosimendan. Drugs (2001) 61:613–627.
- YOSHIKAWA T, BABA A, SUZUKI M et al.: Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. Am. J. Cardiol (2000) 85:1495–1497.
- UKKONEN H, SARASTE M, AKKILA J et al.: Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin. Pharmacol The]: (2000) 68:522–531
- SLAWSKY MT, COLUCCI WS, GOTTLIEB SS et al.: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation (2000) 102:2222–2227.
- NIEMINEN MS, AKKILA J,HASENFUSS G et al.: Hemodynamic and neurohormonal effects of continuous infusion of levosimendan in patients with congestive hear failure. J. Am. Coll. Cardiol (2000) 36:1903–1912.
- COLUCCI WS, ELKAYAM U, HORTON DP et al.: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl. I Med. (2000) 343:246–253.